company background image
300685 logo

Amoy Diagnostics SZSE:300685 Stock Report

Last Price

CN¥19.01

Market Cap

CN¥7.5b

7D

3.6%

1Y

-19.5%

Updated

18 Jul, 2024

Data

Company Financials +

Amoy Diagnostics Co., Ltd.

SZSE:300685 Stock Report

Market Cap: CN¥7.5b

300685 Stock Overview

A diagnostic company, focuses on development and commercialization of diagnostics product for oncology in China and internationally.

300685 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance3/6
Financial Health5/6
Dividends3/6

Amoy Diagnostics Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Amoy Diagnostics
Historical stock prices
Current Share PriceCN¥19.01
52 Week HighCN¥26.69
52 Week LowCN¥14.60
Beta0.67
11 Month Change0.48%
3 Month Change-9.91%
1 Year Change-19.48%
33 Year Change-62.06%
5 Year Change6.80%
Change since IPO362.87%

Recent News & Updates

Amoy Diagnostics' (SZSE:300685) Upcoming Dividend Will Be Larger Than Last Year's

May 27
Amoy Diagnostics' (SZSE:300685) Upcoming Dividend Will Be Larger Than Last Year's

Earnings Report: Amoy Diagnostics Co., Ltd. Missed Revenue Estimates By 6.1%

Apr 24
Earnings Report: Amoy Diagnostics Co., Ltd. Missed Revenue Estimates By 6.1%

Recent updates

Amoy Diagnostics' (SZSE:300685) Upcoming Dividend Will Be Larger Than Last Year's

May 27
Amoy Diagnostics' (SZSE:300685) Upcoming Dividend Will Be Larger Than Last Year's

Earnings Report: Amoy Diagnostics Co., Ltd. Missed Revenue Estimates By 6.1%

Apr 24
Earnings Report: Amoy Diagnostics Co., Ltd. Missed Revenue Estimates By 6.1%

Amoy Diagnostics (SZSE:300685) Could Easily Take On More Debt

Apr 18
Amoy Diagnostics (SZSE:300685) Could Easily Take On More Debt

What Amoy Diagnostics Co., Ltd.'s (SZSE:300685) 33% Share Price Gain Is Not Telling You

Mar 02
What Amoy Diagnostics Co., Ltd.'s (SZSE:300685) 33% Share Price Gain Is Not Telling You

Is Amoy Diagnostics Co., Ltd. (SZSE:300685) Worth CN¥22.0 Based On Its Intrinsic Value?

Mar 01
Is Amoy Diagnostics Co., Ltd. (SZSE:300685) Worth CN¥22.0 Based On Its Intrinsic Value?

Shareholder Returns

300685CN BiotechsCN Market
7D3.6%4.3%1.0%
1Y-19.5%-20.5%-18.2%

Return vs Industry: 300685 exceeded the CN Biotechs industry which returned -20.5% over the past year.

Return vs Market: 300685 underperformed the CN Market which returned -18.2% over the past year.

Price Volatility

Is 300685's price volatile compared to industry and market?
300685 volatility
300685 Average Weekly Movement4.9%
Biotechs Industry Average Movement6.1%
Market Average Movement5.9%
10% most volatile stocks in CN Market9.1%
10% least volatile stocks in CN Market4.0%

Stable Share Price: 300685 has not had significant price volatility in the past 3 months.

Volatility Over Time: 300685's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20081,119Jiemin Luowww.amoydx.com

Amoy Diagnostics Co., Ltd., a diagnostic company, focuses on development and commercialization of diagnostics product for oncology in China and internationally. It offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions for evaluating PARP inhibitor-related biomarkers and advancing targeted treatment research in ovarian cancer; AmoyDx HRD complete panel to detect genetic aberrations across HRR genes and HRD status; AmoyDx master panel, a CGP assay; AmoyDx BRCA Pro panel that covers various protein coding regions, intron/exon boundaries, select introns, and UTR regions of the BRCA1 and BRCA2 genes; AmoyDx handle classic NGS panel to detect multiple gene mutations in cancer patients for treatment; and AmoyDx essential NGS panel to detect EGFR, ALK, ROS1, RET, KRAS, NRAS, PIK3CA, BRAF, HER2, and MET genes in patients with non-small cell lung cancer and colorectal cancer using FFPE or liquid biopsy samples. The company also provides AmoyDx handle HRR NGS panel for detection of somatic and germline variants; AmoyDx pan lung cancer PCR panel, a tissue-based real-time qPCR assay for in vitro diagnostics; AmoyDx myeloid blood cancer panel; AmoyDx comprehensive panel, a sequencing-based test capable of detecting a range of alterations; AmoyDx PD-L1 (E1L3N) assay; and AmoyDx handle melanoma NGS panel to detect single nucleotide variants, insertions, and deletions within pivotal melanoma tumor genes.

Amoy Diagnostics Co., Ltd. Fundamentals Summary

How do Amoy Diagnostics's earnings and revenue compare to its market cap?
300685 fundamental statistics
Market capCN¥7.46b
Earnings (TTM)CN¥268.37m
Revenue (TTM)CN¥1.08b

28.0x

P/E Ratio

6.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
300685 income statement (TTM)
RevenueCN¥1.08b
Cost of RevenueCN¥181.70m
Gross ProfitCN¥899.93m
Other ExpensesCN¥631.56m
EarningsCN¥268.37m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Jul 30, 2024

Earnings per share (EPS)0.68
Gross Margin83.20%
Net Profit Margin24.81%
Debt/Equity Ratio3.0%

How did 300685 perform over the long term?

See historical performance and comparison

Dividends

0.8%

Current Dividend Yield

22%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.